- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03766867
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
August 28, 2019 updated by: H. Lundbeck A/S
Interventional, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Initial Administration of 25 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study consists of a 7-day double-blind Treatment Period (Day 0 to Day 6)
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Burgas, Bulgaria
- Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004)
-
Kardzhali, Bulgaria
- SPH - Kardzhali, EOOD (BG1005)
-
Kazanlak, Bulgaria
- MHAT "Dr. Hristo Stambolski", EOOD (BG1001)
-
Novi Iskar, Bulgaria
- State Psychiatric Hospital "Sv. Ivan Rilski" (BG1009)
-
Pleven, Bulgaria
- UMHAT 'Dr. Georgi Stranski', EAD (BG1006)
-
Ruse, Bulgaria
- MHC - Ruse, EOOD (BG1007)
-
Tsarev Brod, Bulgaria
- State Psychiatric Hospital (BG1008)
-
Vratsa, Bulgaria
- Mental Health Center-Vratsa EOOD (BG1002)
-
-
-
-
-
Tallinn, Estonia
- Marienthali Kliinik (EE2001)
-
Tartu, Estonia
- Tartu University Hospital (EE2002)
-
-
-
-
-
Daugavpils, Latvia
- Psychoneurological Hospital of Daugavpils (LV3003)
-
Riga, Latvia
- Riga Centre of Psychiatry and Narcology (LV3002)
-
Strenči, Latvia
- Psychoneurological Hospital of Strenci (LV3001)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient has recurrent MDD, diagnosed according to DSM-5® and confirmed using the Mini-International Neuropsychiatric Interview (MINI).
- The patient has a MADRS total score ≥ 30 at the Screening Visit.
- As part of standard of care treatment, the patient is to be admitted to hospital due to the severity of the depressive symptoms and is willing to remain hospitalized for the duration of the study treatment period.
- The patient has had the current MDE for ≥3 months but less than 12 months.
- The patient has received treatment for the current episode with an SSRI/SNRI monotherapy (citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, sertraline) at an approved dose for at least 6 weeks.
Exclusion criteria:
-The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria), established as the primary diagnosis, other than MDD, as assessed using the MINI or another diagnostic interview
Other in- and exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
oral administration once daily
|
EXPERIMENTAL: Vortioxetine
|
1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
10 mg, tablets, oral administration once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (Day 0) to Day 1 (24 h post-infusion) in MADRS-6 subscale score
Time Frame: From baseline (Day 0) to Day 1 (24 h post-infusion)
|
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects.
Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom).
Definitions of severity are provided at two-point intervals.
The total score of the ten items ranges from 0 to 60.
The primary endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.
|
From baseline (Day 0) to Day 1 (24 h post-infusion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (Day 0) to Day 3 in MADRS-6 subscale score
Time Frame: From baseline (Day 0) to Day 3
|
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects.
Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom).
Definitions of severity are provided at two-point intervals.
The total score of the ten items ranges from 0 to 60.
The endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.
|
From baseline (Day 0) to Day 3
|
Change from baseline (Day 0) to Day 7 in MADRS-6 subscale score
Time Frame: From baseline (Day 0) to Day 7
|
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects.
Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom).
Definitions of severity are provided at two-point intervals.
The total score of the ten items ranges from 0 to 60.
The endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.
|
From baseline (Day 0) to Day 7
|
Change in MADRS total score from baseline to Day 1, Day 3, Day 7
Time Frame: From baseline to Day 1, Day 3, Day 7
|
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects.
Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom).
Definitions of severity are provided at two-point intervals.
The total score of the ten items ranges from 0 to 60.
|
From baseline to Day 1, Day 3, Day 7
|
≥50% decrease in MADRS total score from baseline on Day 1 and Day 3
Time Frame: On Day 1 and Day 3
|
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects.
Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom).
Definitions of severity are provided at two-point intervals.
The total score of the ten items ranges from 0 to 60.
|
On Day 1 and Day 3
|
CGI-I score at Day 1, Day 3, Day 7
Time Frame: At Day 1, Day 3, Day 7
|
The Clinical Global Impression (CGI) provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I).
The CGI-I provides the clinician's impression of the patient's improvement (or worsening).
The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
|
At Day 1, Day 3, Day 7
|
CGI-I response (defined as CGI-I score ≤2) on Day 1 and 3
Time Frame: At Day 1 and 3
|
The Clinical Global Impression (CGI) provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I).
The CGI-I provides the clinician's impression of the patient's improvement (or worsening).
The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
|
At Day 1 and 3
|
Change from baseline in CGI-S score to Day 1, Day 3, Day 7
Time Frame: From baseline to Day 1, Day 3, Day 7
|
The Clinical Global Impression (CGI) provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I).
The CGI-S provides the clinician's impression of the patient's current state of mental illness.
The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
|
From baseline to Day 1, Day 3, Day 7
|
CL/F of vortioxetine
Time Frame: Day 0, Day 1, Day 7
|
Total plasma clearance of vortioxetine
|
Day 0, Day 1, Day 7
|
Cav
Time Frame: Day 0, Day 1, Day 7
|
average plasma concentration during a steady-state day
|
Day 0, Day 1, Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 3, 2018
Primary Completion (ACTUAL)
July 31, 2019
Study Completion (ACTUAL)
August 28, 2019
Study Registration Dates
First Submitted
December 5, 2018
First Submitted That Met QC Criteria
December 5, 2018
First Posted (ACTUAL)
December 6, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 29, 2019
Last Update Submitted That Met QC Criteria
August 28, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Vortioxetine
Other Study ID Numbers
- 17915A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Vortioxetine infusion 25 mg
-
Zydus Lifesciences LimitedRecruitingAmyotrophic Lateral SclerosisIndia
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
Idorsia Pharmaceuticals Ltd.CompletedHepatic ImpairmentSwitzerland
-
Idorsia Pharmaceuticals Ltd.Completed
-
Repros Therapeutics Inc.Completed
-
H. Lundbeck A/SCompletedPharmacokineticsChina
-
Insmed IncorporatedCompletedNon-Cystic Fibrosis BronchiectasisUnited States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
-
Idorsia Pharmaceuticals Ltd.CompletedInsomnia DisorderUnited States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
-
Novartis PharmaceuticalsCompleted